Carbs, Fats and Protein: One molecule to rule them all?
Duke researchers have identified a key fork in the road for the way the liver deals with carbohydrates, fats and protein. They say it could be a promising new target for combating the pandemics of fatty liver disease and prediabetes.
The finding is an outgrowth of the Duke Molecular Physiology Institute’s “retro-translation” approach, in which bloodstream markers of a particular disease are identified by broad screens and then “taken back into animal models to figure out what that signal means,” said Phillip White, an assistant professor of medicine who led the study.
In this case, White and colleagues were pursuing a cluster of amino acids — breakdown products of protein metabolism — that seemed to signal insulin resistance. They’re called branched-chain amino acids, or BCAA, and had been identified in 2009 as a robust marker of obesity and insulin resistance in humans by Duke researchers led by Christopher Newgard, the director of the Duke Molecular Physiology Institute.
The association between BCAA and insulin resistance had been present in the literature dating back to a 1969 study that appeared in the New England Journal of Medicine. And they have since been shown to be highly predictive of future diabetes development by the landmark Framingham Heart study.
“These metabolites travel together with poor metabolic health,” White said. “There’s a longstanding historical record of this, but we don’t know what it means.”
In probing the biochemistry of how BCAAs come to be more abundant in obesity and insulin-resistance, researchers have found that different organ systems handle their breakdown in different ways. In the liver, which stores more fat and produces more glucose in prediabetes, it turns out that the molecular components that execute BCAA breakdown are turned off by a single regulatory switch.
Two molecules, a kinase and a phosphatase, work in opposition to flip this regulatory switch that controls the break down of BCAA. The balance of these molecules determines whether BCAAs are broken down or accumulate.
“Well, what if we turn it back on?” White asked. “We can take away the inhibitory signal, the kinase, or add more of the activating signal, the phosphatase.” This approach was aided by a collaboration with the group of Drs. David Chuang and Max Wynn at the University of Texas Southwestern Medical Center, Dallas, who had discovered a drug that inhibits the kinase.
When the researchers inhibited the kinase or activated the phosphatase, the results were almost identical. Within a week in a rat model of pre-diabetes, activating BCAA breakdown reduced fat deposition in the liver and improved glucose regulation without altering body weight.
“This particular rat model (the Zucker fatty rat) is an extreme model of obesity and metabolic disease, so if you can get an improvement in a week, that’s really significant,” White said.
Through these experiments, the Duke team linked its findings to an enzyme that plays an important role in fat production in the liver. They showed that this enzyme, called ATP-citrate lyase, interacts with and is regulated by the same kinase and phosphatase that regulate BCAA metabolism. In a series of experiments, they established how and where these three factors interact in different parts of liver cells.
Working with Duke colleague Mark Herman, the researchers also found that a high-fructose diet (like drinking a lot of sugary soda), “creates an imbalance in the levels of the kinase and phosphatase as part of a larger program that promotes fat accumulation in the liver,” White said. Kinase activity goes up, phosphatase activity goes down — more bad guy, less good guy — leading to more liver fat and poorer metabolic health.
“This helps to explain how and why BCAA are associated with disordered fat metabolism that can lead to type 2 diabetes,” said Newgard, who has worked on BCAA in metabolic disease for more than a decade.
“Chris’ group has been a real leader in showing the importance of this,” said Robert Gerszten MD, director of clinical and translational research for the Massachusetts General Hospital Heart Center. “There were hints about (BCAA) long ago, but the scientific world was sort of asking ‘what’s the cart and what’s the horse?’” said Gerszten, who was not a part of this study.
“There’s growing evidence to suggest that BCAA isn’t just a passive marker of diabetes, but may actually play a role in driving the disease,” Gerszten said. “It gives us the motivation to test whether changes in the amino acid intake in our diets would be worth exploring.”
These findings are limited by the use of only one kind of animal model and the short duration of the study, but White is optimistic that longer-term studies in other animal models will bear them out.
“Although much work remains to be done there’s a potential for this to be a new target for treating fatty liver disease,” White said.
Learn more: DIABETES RESEARCHERS FIND SWITCH FOR FATTY LIVER DISEASE
The Latest on: Fatty liver disease
[google_news title=”” keyword=”fatty liver disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Fatty liver disease
- Intermittent Fasting Shields Against Liver Canceron May 9, 2024 at 12:37 pm
Patients with liver cancer experience greater benefits from a 5:2 dietary pattern compared to a 6:1 regimen, while 24-hour fasting periods prove effective.
- Intermittent fasting protects against liver inflammation, liver cancer: Studyon May 9, 2024 at 5:18 am
Intermittent fasting has been found in multiple studies to be an effective way to lose weight and alleviate some metabolic disorders. Heikenwalder's team has now investigated in mice if this method ...
- Winners of the American Liver Foundation 2024 Poster Competition Announcedon May 9, 2024 at 5:04 am
Winners from the American Liver Foundation's 2024 Liver Health Poster Competition were announced today. This competition showcases posters and a brief video created by early career healthcare ...
- What Happens If Non-alcoholic Fatty Liver Disease Remain Untreated? A Review By Doctorson May 8, 2024 at 2:28 pm
Expert opinion from Akshara Mudigonda MBBS · 2 years of experience · India Non-alcoholic fatty liver disease(NAFLD) is strongly associated with obesity, dyslipidemia, insulin resistance and type 2 ...
- MRE-liver stiffness measure better for varices in NAFLD cirrhosison May 8, 2024 at 11:01 am
For patients with obesity and nonalcoholic fatty liver disease (NAFLD) compensated cirrhosis (CC), liver stiffness measurement (LSM) by magnetic resonance elastography (MRE) is significantly higher ...
- Intermittent fasting protects against liver inflammation and liver canceron May 6, 2024 at 4:59 pm
Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tübingen have now ...
- Gut bacteria sometimes get people drunk, leading to DUIs and liver diseaseon May 5, 2024 at 3:00 am
Though it's a rare condition, a woman was acquitted of her DUI charge in 2016 after doctors diagnosed her with the same syndrome. She had a blood alcohol level four times the legal limit.
- If you have fatty liver disease then do not panic, you can control it with these methods even without taking medicineon May 1, 2024 at 10:23 pm
Fatty liver disease, characterized by the accumulation of fat in liver cells, is becoming increasingly prevalent worldwide. The condition ca..|News Track ...
- Metabolic-associated fatty liver disease: Know what causes it and how to prevent iton April 28, 2024 at 9:00 am
The study uncovers increased cardiovascular risk in type 2 diabetes patients with MAFLD. Lifestyle changes like heart-healthy diets and exercise are c ...
via Bing News